Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic kidney disease markets reached a value of US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 11.0 Billion by 2034, exhibiting a growth rate (CAGR) of 8.27% during 2024-2034.
The chronic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic kidney disease is a medical condition in which progressive damage and gradual loss of renal function occur over time. This can result in the buildup of excess fluid, electrolytes, and waste from the blood in the body, causing severe health problems. The disease exhibits mild to no symptoms in the early stages, but over time people may experience nausea, loss of appetite, vomiting, fatigue, weakness, muscle cramps, shortness of breath, dry and itchy skin, swelling of feet and ankles, etc. The other common indications of this ailment include sleep problems, unexplained weight loss, decreased mental sharpness, chest pain, high blood pressure, water-electrolyte imbalance, abnormal heart rhythm, failure to thrive, insufficient urine production, etc. Diagnosing the condition usually requires a review of the patient's symptoms and medical history, along with a physical and neurological exam. The healthcare provider may perform several investigations, such as blood workups, imaging studies, urine tests, etc., to determine the severity of the disease. Additionally, a kidney biopsy is recommended, which involves removing a sample of renal tissue and examining it under a microscope.
The increasing cases of high blood pressure and diabetes, which can exert strain on the renal blood vessels and cause damage, are primarily driving the chronic kidney disease market. In addition to this, the rising incidence of renal stones, enlarged prostate, and some cancer that result in prolonged obstruction of the urinary tract are also bolstering the market growth. Furthermore, the inflating utilization of effective drugs, including diuretics, angiotensin-converting enzyme (ACE) inhibitors, statins, etc., to treat the underlying symptoms and slow the progression of the illness is acting as another significant growth-inducing factor. Apart from this, the escalating application of peritoneal dialysis therapy, which uses the lining of the abdominal cavity to remove waste and excess fluids from the body, is further creating a positive outlook for the market. Additionally, the emerging popularity of sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and canagliflozin, for treating this condition since they can reduce albuminuria and enhance renal outcomes is expected to drive the chronic kidney disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic kidney disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic kidney disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic kidney disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic kidney disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic kidney disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic kidney disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic kidney disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic kidney disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic kidney disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic kidney disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic kidney disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic kidney disease across the seven major markets?
What is the size of the chronic kidney disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic kidney disease?
What will be the growth rate of patients across the seven major markets?
Chronic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic kidney disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic kidney disease market?
What are the key regulatory events related to the chronic kidney disease market?
What is the structure of clinical trial landscape by status related to the chronic kidney disease market?
What is the structure of clinical trial landscape by phase related to the chronic kidney disease market?
What is the structure of clinical trial landscape by route of administration related to the chronic kidney disease market?
The chronic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic kidney disease is a medical condition in which progressive damage and gradual loss of renal function occur over time. This can result in the buildup of excess fluid, electrolytes, and waste from the blood in the body, causing severe health problems. The disease exhibits mild to no symptoms in the early stages, but over time people may experience nausea, loss of appetite, vomiting, fatigue, weakness, muscle cramps, shortness of breath, dry and itchy skin, swelling of feet and ankles, etc. The other common indications of this ailment include sleep problems, unexplained weight loss, decreased mental sharpness, chest pain, high blood pressure, water-electrolyte imbalance, abnormal heart rhythm, failure to thrive, insufficient urine production, etc. Diagnosing the condition usually requires a review of the patient's symptoms and medical history, along with a physical and neurological exam. The healthcare provider may perform several investigations, such as blood workups, imaging studies, urine tests, etc., to determine the severity of the disease. Additionally, a kidney biopsy is recommended, which involves removing a sample of renal tissue and examining it under a microscope.
The increasing cases of high blood pressure and diabetes, which can exert strain on the renal blood vessels and cause damage, are primarily driving the chronic kidney disease market. In addition to this, the rising incidence of renal stones, enlarged prostate, and some cancer that result in prolonged obstruction of the urinary tract are also bolstering the market growth. Furthermore, the inflating utilization of effective drugs, including diuretics, angiotensin-converting enzyme (ACE) inhibitors, statins, etc., to treat the underlying symptoms and slow the progression of the illness is acting as another significant growth-inducing factor. Apart from this, the escalating application of peritoneal dialysis therapy, which uses the lining of the abdominal cavity to remove waste and excess fluids from the body, is further creating a positive outlook for the market. Additionally, the emerging popularity of sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin and canagliflozin, for treating this condition since they can reduce albuminuria and enhance renal outcomes is expected to drive the chronic kidney disease market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic kidney disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic kidney disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic kidney disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic kidney disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic kidney disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic kidney disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic kidney disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic kidney disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic kidney disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic kidney disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic kidney disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic kidney disease across the seven major markets?
What is the size of the chronic kidney disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic kidney disease?
What will be the growth rate of patients across the seven major markets?
Chronic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic kidney disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic kidney disease market?
What are the key regulatory events related to the chronic kidney disease market?
What is the structure of clinical trial landscape by status related to the chronic kidney disease market?
What is the structure of clinical trial landscape by phase related to the chronic kidney disease market?
What is the structure of clinical trial landscape by route of administration related to the chronic kidney disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC KIDNEY DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC KIDNEY DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC KIDNEY DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC KIDNEY DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC KIDNEY DISEASE - UNMET NEEDS
10 CHRONIC KIDNEY DISEASE - KEY ENDPOINTS OF TREATMENT
11 CHRONIC KIDNEY DISEASE - MARKETED PRODUCTS
11.1 List of Chronic Kidney Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Farxiga (Dapagliflozin) - AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC KIDNEY DISEASE - PIPELINE DRUGS
12.1 List of Chronic Kidney Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 RTA 402 - Reata Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 US APR2020 - Kibow Biotech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ALLN-346 - Allena Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BI685509 - Boehringer Ingelheim
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC KIDNEY DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC KIDNEY DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC KIDNEY DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Kidney Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Kidney Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Kidney Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Kidney Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Kidney Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Kidney Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Kidney Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Kidney Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Kidney Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Kidney Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Kidney Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Kidney Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Kidney Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Kidney Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Kidney Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Kidney Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Kidney Disease - Access and Reimbursement Overview
16 CHRONIC KIDNEY DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC KIDNEY DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC KIDNEY DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC KIDNEY DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC KIDNEY DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC KIDNEY DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC KIDNEY DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC KIDNEY DISEASE - UNMET NEEDS
10 CHRONIC KIDNEY DISEASE - KEY ENDPOINTS OF TREATMENT
11 CHRONIC KIDNEY DISEASE - MARKETED PRODUCTS
11.1 List of Chronic Kidney Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Farxiga (Dapagliflozin) - AstraZeneca
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC KIDNEY DISEASE - PIPELINE DRUGS
12.1 List of Chronic Kidney Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 RTA 402 - Reata Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 US APR2020 - Kibow Biotech
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ALLN-346 - Allena Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BI685509 - Boehringer Ingelheim
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC KIDNEY DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC KIDNEY DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC KIDNEY DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Kidney Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Kidney Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Kidney Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Kidney Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Kidney Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Kidney Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Kidney Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Kidney Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Kidney Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Kidney Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Kidney Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Kidney Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Kidney Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Kidney Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Kidney Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Kidney Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Kidney Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Kidney Disease - Access and Reimbursement Overview
16 CHRONIC KIDNEY DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC KIDNEY DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC KIDNEY DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
